Paris, France, 4 July 2022 – T-Heart, a privately-owned medtech company developing a truly novel and differentiated transcatheter tricuspid prosthetic heart valve that is specifically designed for tricuspid regurgitation, today announced it has appointed Stephane Delaloye as Acting Chief Technical Officer. In this role, he will be responsible for coordinating T-Heart’s R&D activities and driving an efficient development plan.
Mr. Delaloye joins T-Heart with more than 25 years of experience in the development of minimally invasive medical products. He was most recently VP R&D at Symetis (Boston Scientific). He has held other management positions at Biotronik and Schneider Europe with an expertise in the development of structural heart and interventional devices from the idea to the product commercialization. Stéphane Delaloye holds an MSc / PhD in Mechanical Engineering from the Swiss Federal Institute of Technology in Zürich.
The addition of Mr. Delaloye to T-Heart’s reinforces its leadership team in preparation for the next crucial development steps prior to the initiation of the clinical trials in tricuspid regurgitation patients.
TR is a progressive condition in which blood leaks backward through the tricuspid valve, potentially leading to heart failure and death. The condition affects 3 million patients in US & Europe and less than 1% receive surgical treatment today associated with a high mortality rate.
Soad El Ghazouani, CEO of T-Heart, said: “We’re delighted to have Stephane join the team as we continue to advance our ambitious development plan. His extensive experience in developing minimally invasive devices in the cardiovascular space will bring new expertise to the company and help us optimize our processes as we move forward. We are confident that his knowledge and skills will enable him to contribute significantly to moving our product into the clinic, as we remain focused on our goal of bringing a solution to tricuspid regurgitation patients.”
Mr. Delaloye said: “I am thrilled to be joining T-Heart in this important new role. T-Heart has made remarkable advancements with its unique transcatheter tricuspid heart valve replacement product and I look forward to leveraging my experience to continue executing the company’s ambitious development and regulatory plans”
CONTACTS
T-HEART
Soad El-Ghazouani +33 1 85 73 27 05
IBIONEXT
Alexia Perouse
ABOUT T-HEART
T-Heart is a French medical device company focused on the treatment of Tricuspid Regurgitation, a true medical unmet need. Tricuspid regurgitation is a progressive condition in which blood leaks backward through the tricuspid valve, potentially leading to heart failure and death. The transcatheter tricuspid market represents a $3.0+ billion potential opportunity, although currently, limited treatment options exist to address this market.
T-Heart has developed a truly novel and differentiated transcatheter tricuspid prosthetic heart valve that is specifically designed for tricuspid heart valve regurgitation, thereby addressing the specific anatomical challenges. In addition, T-Heart’s unique design enables the interventional cardiologist to replace the diseased tricuspid valve with a simple one-step technique and allows for broad applicability to a larger patient population with minimal device sizes.
Since its inception, T-Heart has assembled an impressive team, comprised of management and external experts, has successfully proved the concept through pre-clinical testing and initiated its Q-Sub for EFS with the FDA.
For more information: www.theartvalve.com
ABOUT IBIONEXT
iBionext is a venture capital firm that supports and finances the development of companies with a strong technological breakthrough in HealthTech. Launched as a network of start-ups in 2012, iBionext is the first French company builder and investment fund to operationally cover the entire value chain of its investments, from creation to growth. All iBionext companies are grouped on a single site, in the “Passage de l’Innovation”, Paris, France. Since its creation, the iBionext network has enabled the creation of 9 companies – Pixium Vision (Euronext: ALPIX), GenSight Biologics (Euronext: SIGHT), Tissium, Prophesee, ChronoLife, BrainEver, Tilak Healthcare, BrainEver, GrAI Matter Labs and T-Heart, which have raised over €600M. More than 18 clinical trials were completed, are underway or completed worldwide and 400+ employees specializing in cutting-edge sectors have joined these companies.
For more information: www.ibionext.com